Three decades of glucose‐lowering therapy in patients at high cardiovascular risk — A real‐world analysis
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16084 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Magdalena Neyer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Private University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein. Hauptthemen laut MEDLINE: Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Heart Disease Risk Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Aim
Over recent years, therapy options and strategies for type 2 diabetes mellitus (T2DM) have developed substantially. This study investigated glucose‐lowering treatment in patients with high cardiovascular risk over three decades. Materials and Methods A total of 2158 patients undergoing elective coronary angiography at a tertiary care hospital in Europe were included in three sequential observational studies (OS): OS1 (1999–2000; n = 672), OS2 (2005–2008; n = 1005) and OS3 (2022–2023; n = 481). Sociodemographic data, patient‐reported medication, medical histories and blood samples were analysed.
Results
A clear trend towards more complex glucose‐lowering therapies was found. A wider array of glucose‐lowering drugs was used over time (OS1: 11; OS2: 21; OS3: 25) and the number of different drugs used in combination therapy in a single patient increased to a maximum of five in OS3. Furthermore, substantial differences in applied medication regimens were observed: Sodium‐glucose cotransporter‐2 inhibitors were the most frequently reported substance class (34.0% of total reported glucose‐lowering drugs) in OS3, whilst metformin remained a key component (OS1: 33.9%; OS2: 41.8%; OS3: 32.0%). Other drug classes like sulfonylureas were largely replaced. A total of 69.2% of patients in OS3 achieved an HbA1c level of < 7% (vs. OS1: 51.9%, OS2: 54.7%; p trend < 0.001). Over 25% of patients with T2DM were newly diagnosed at admission (OS1: 43.8%, OS2: 29.7%, OS3: 27.2%; p trend < 0.001) and had therefore no diabetes‐related medication.
Conclusion
These real‐world data emphasize a marked shift in T2DM treatment towards novel substance classes. However, the use of incretin mimetics remained low. Significantly more patients reached HbA1c targets in the most recent cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Private University in the Principality of Liechtenstein (UFL), Triesen, Liechtenstein.
- Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT), Feldkirch, Austria.
- Department of Internal Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
- Landeskrankenhaus-Betriebsgesellschaft, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
- Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
- Medical Central Laboratories, Feldkirch, Austria.
ORCID-Profile: Magdalena Neyer, Johannes B Vogel, Pascal Elsner, Andreas Festa
Zitieren
APA
Neyer, M., Vogel, J. B., Elsner, P., Kuehrer, H., Saely, C. H., Muendlein, A., Vonbank, A., Mader, A., Festa, A., Drexel, H., & Leiherer, A. (2025). Three decades of glucose‐lowering therapy in patients at high cardiovascular risk — A real‐world analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16084
Vancouver
Neyer M, Vogel JB, Elsner P, Kuehrer H, Saely CH, Muendlein A, et al. Three decades of glucose‐lowering therapy in patients at high cardiovascular risk — A real‐world analysis. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16084
BibTeX
@article{Neyer2025,
author = {Neyer, Magdalena and Vogel, Johannes B and Elsner, Pascal and Kuehrer, Heike and Saely, Christoph H and Muendlein, Axel and Vonbank, Alexander and Mader, Arthur and Festa, Andreas and Drexel, Heinz and Leiherer, Andreas},
title = {Three decades of glucose‐lowering therapy in patients at high cardiovascular risk — A real‐world analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16084}
}
EUVIMED